GROWTH / DIRECT CATALOG PRICING
Ipamorelin
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue and ghrelin-receptor agonist; PubChem records the sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2.
- Format
- Lyophilized research vial
- Listed formats
- 2
- Available now
- 2
- Catalog class
- Growth
Choose a listed format
- 5 mg$39.00 · AvailableSelect format
- 10 mg$74.00 · AvailableSelect format
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue and ghrelin-receptor agonist; PubChem records the sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2.
The growth classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Growth
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- 2 formats currently orderable
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue and ghrelin-receptor agonist; PubChem records the sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2.
- Research covered
- A dose-escalation PK/PD study infused ipamorelin in healthy male volunteers and measured circulating ipamorelin and growth hormone. The study characterizes short-term disposition and a hormone response under controlled infusion conditions.
- Important limit
- The study was small, male-only, acute, and did not evaluate the catalog's vial presentations, long-term outcomes, or an unverified retail material. It is not evidence for a treatment claim.
- Authoritative sources
FACTUAL FAQ
Ipamorelin catalog questions
What formats are currently listed?
5 mg, 10 mg. Current price and stock state appear above.
What did researchers study?
A dose-escalation PK/PD study infused ipamorelin in healthy male volunteers and measured circulating ipamorelin and growth hormone. The study characterizes short-term disposition and a hormone response under controlled infusion conditions.
What is the most important evidence limit?
The study was small, male-only, acute, and did not evaluate the catalog's vial presentations, long-term outcomes, or an unverified retail material. It is not evidence for a treatment claim.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →